AGER and type 2 diabetes mellitus: Our results are consistent with previous reports that demonstrated increased circulating levels of sRAGE [32, 37, 38] and sICAM-1 [32, 39–41] in both patients with type 1 and type 2 diabetes mellitus compared to nondiabetic controls.